Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Short-term Investments (2019 - 2025)

Pulmonx (LUNG) has disclosed Short-term Investments for 6 consecutive years, with $8.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Short-term Investments fell 82.85% to $8.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $8.8 million, a 82.85% decrease, with the full-year FY2024 number at $30.6 million, down 8.87% from a year prior.
  • Short-term Investments was $8.8 million for Q2 2025 at Pulmonx, down from $14.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $51.1 million in Q2 2024 to a low of $8.8 million in Q2 2025.
  • A 5-year average of $29.9 million and a median of $33.6 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: surged 318.17% in 2022, then crashed 82.85% in 2025.
  • Pulmonx's Short-term Investments stood at $31.6 million in 2021, then rose by 24.84% to $39.4 million in 2022, then fell by 14.84% to $33.6 million in 2023, then dropped by 8.87% to $30.6 million in 2024, then crashed by 71.35% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Short-term Investments are $8.8 million (Q2 2025), $14.1 million (Q1 2025), and $30.6 million (Q4 2024).